AI Article Synopsis
- A case study is presented on a patient experiencing a Medtronic HeartWare ventricular assist device (HVAD) pump failure-to-restart, highlighting the risks still faced by patients since the device was withdrawn from the market in June 2021.
- Despite the device's market withdrawal, around 4,000 patients globally continue to rely on HVAD support, putting them at risk for serious complications.
- The report introduces a new HVAD controller that successfully restarted a malfunctioning pump, demonstrating its potential to prevent life-threatening situations and reduce the need for device replacement.
Article Abstract
We report a case of Medtronic HeartWare ventricular assist device (HVAD) pump failure-to-restart. Despite HVAD withdrawal from the market in June 2021, up to 4,000 patients remain on HVAD support worldwide, and many are at high risk for this serious complication. This report describes the first-in-man use of a new HVAD controller that restarted a defective HVAD pump and avoided a fatal outcome. This new controller has the potential of preventing unnecessary VAD exchanges and saving lives.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MAT.0000000000001911 | DOI Listing |
Publication Analysis
Top Keywords
hvad pump
8
hvad
6
first-in-man modified
4
modified controller
4
controller resolve
4
resolve hvad
4
hvad failure-to-restart
4
failure-to-restart report
4
report case
4
case medtronic
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!